CJC-1295 no DAC (5mg)
Specyfikacja techniczna
| Czystość (HPLC) | ≥99% (HPLC) |
| Numer CAS | 863288-34-0 |
| Forma | White lyophilized powder |
| Przechowywanie | -20°C |
| Sekwencja | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Masa cząsteczkowa | 3,367.89 g/mol |
| Forma soli | Acetate |
| Rozpuszczalność | Soluble in water |
CJC-1295 no DAC (5mg)
Cena katalogowa w EUR · HU, SK, CZ, PL
- Eurozone (EUR)44,99 EUR
- Węgry (HU)44,99 EUR≈ 17 996 Ft
- Słowacja (SK)44,99 EUR
- Czechy (CZ)44,99 EUR≈ 1 125 Kč
- Polska (PL)44,99 EUR≈ 191,21 zł
Ta sama cena katalogowa w EUR przy dostawie na Węgry, Słowację, Czechy i Polskę. Płatność w EUR.
Orientacyjne kwoty HUF, CZK i PLN przeliczone z EUR; Słowacja stosuje EUR. Kursy przybliżone. Płatność w EUR.
CJC-1295 (bez DAC) — analog GHRH o krótszym okresie półtrwania niż wariant z DAC; do modeli pulsacyjnego uwalniania GH z przysadki. Wyłącznie RUO — do badań laboratoryjnych; nie do spożycia przez ludzi.
Wyłącznie do badań laboratoryjnych.
Nie do spożycia przez ludzi, zastosowań weterynaryjnych ani diagnostycznych.
From the Peptide Explorer
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Key Mechanisms
- ›GHRH receptor agonism
- ›Pulsatile GH release promotion
- ›Synergy with GHSR agonists (ipamorelin)
- ›Somatostatin-sensitive (preserves feedback)
- ›Enhanced half-life via amino acid substitutions
Primary Research Areas
- ›GH axis physiology
- ›Pulsatile GH release
- ›Body composition
- ›Combined secretagogue protocols
Key Research Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Overview
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Origin: Modified analog of Growth Hormone Releasing Hormone (GHRH) 1-29
Mechanism of Action
- GHRH receptor agonism
- Pulsatile GH release promotion
- Synergy with GHSR agonists (ipamorelin)
- Somatostatin-sensitive (preserves feedback)
- Enhanced half-life via amino acid substitutions
Primary Research Areas
- GH axis physiology
- Pulsatile GH release
- Body composition
- Combined secretagogue protocols
Key Published Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
CJC-1295 no DAC (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Specyfikacja badawcza
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobacz standardy jakości →
Przechowywanie i obsługa
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water